Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Brokerages

Immunome, Inc. (NASDAQ:IMNM) has earned an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have covered the stock in the last year is $28.83.

Several equities research analysts have recently weighed in on IMNM shares. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Stephens started coverage on shares of Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Piper Sandler cut their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th.

Immunome Trading Up 13.5 %

Shares of IMNM opened at $11.15 on Tuesday. Immunome has a twelve month low of $6.93 and a twelve month high of $30.96. The company has a market cap of $695.98 million, a P/E ratio of -1.37 and a beta of 1.82. The company’s fifty day simple moving average is $12.49 and its 200-day simple moving average is $13.55.

Insiders Place Their Bets

In other news, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now directly owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Philip Tsai purchased 21,000 shares of the stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the acquisition, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. This represents a ? increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 102,862 shares of company stock worth $978,045 in the last three months. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Institutional investors have recently modified their holdings of the company. Quest Partners LLC bought a new stake in shares of Immunome in the 2nd quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Immunome in the 2nd quarter valued at approximately $97,000. Arizona State Retirement System raised its position in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of Immunome in the 2nd quarter valued at approximately $206,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.